Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hodgkin's Disease: early-phase trial registry
4 of 22 indexed Hodgkin's Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 4 currently recruiting · #756 of 28,707 conditions by registered trial count
Hodgkin's Disease: 22 US clinical trials tracked, 4 recruiting.
Hodgkin's Disease is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 6 of these trials.
Enrollment posture brief
Registry condition hodgkins-disease
OPEN 4 | RECR 18% | LATE 0 | EARLY 15 | RANK #756 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Pancreas (18% recruiting · 11 trials)
Hodgkin's Disease lists 4 open slots (18% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hodgkin's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hodgkin's Disease is recruiting below its size-band peers.
4 of 22 indexed trials (18.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hodgkin's Disease research.
Dana-Farber Cancer Institute accounts for 6 of 22 trials (27.3%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Hodgkin's Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 21 trials that report a genuine target (sentinel values excluded). 14 of those (66.7%) plan for fewer than 100 participants.
-
Hodgkin's Disease research is mostly interventional.
17 interventional and 5 observational studies make up this index (77.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Stanford University
NCT00398177
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Dana-Farber Cancer Institute
NCT00131014
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Baylor College of Medicine
NCT01555892
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
Dana-Farber Cancer Institute
NCT00165425
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Baylor College of Medicine
NCT00368082
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT00597714
Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers
Memorial Sloan Kettering Cancer Center
NCT00608452
Mantle Irradiation for Hodgkin's Disease
Dana-Farber Cancer Institute
NCT00165269
Amifostine for Head and Neck Irradiation in Lymphoma
Dana-Farber Cancer Institute
NCT00136474
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
National Cancer Institute (NCI)
NCT00001430
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Duke University
NCT01904175
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
NCT00133367
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT00667615
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Dana-Farber Cancer Institute
NCT00165308
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
Memorial Sloan Kettering Cancer Center
NCT00592111
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
NCT00901225
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
GPCR Therapeutics
NCT01458288
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Fate Therapeutics
NCT01527838
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Hodgkin's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hodgkin's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hodgkin's Disease page
22 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Hodgkin's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Hodgkin's Disease trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hodgkin's Disease condition card totals 22 registered trials; most-linked intervention G-CSF; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.